Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

This innovative CBGM system, designed for continuous, accurate glucose monitoring over three years without any on-body external component, offers a more convenient and less intrusive alternative ...

Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...

Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

The CBGM is a long-term implantable device with no on-body external component, designed for three years of continuous, accurate blood glucose monitoring, offering a more convenient and less ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...

Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

Glucotrack’s CEO Paul V. Goode told Medical Device Network: "In a survey of 757 patients, we found significant interest in an implantable continuous glucose monitor. The most appealing features ...

Dec. 09, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...

Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...